AUROBINDO PHARMA LTD.

Aurobindo is a Young Indian Pharmaceutical company born in Year 1986. Aurobindo's mission is to become the most valued Pharma partner for the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products complying to the highest regulatory standards. A well integrated pharma company with focus on formulations. Vertically Integrated pharmaceutical company with huge capacity giving economies of scale. In house R&D for rapid filing of Patents, ANDAs & DMFs Global Regulatory approved manufacturing base Global presence with manufacturing infrastructure, strategic alliances, subsidiaries and joint ventures. Exporting to 125+ countries with 70%+ of revenues from international operations Well spread global marketing network through 40 subsidiaries Employee base of 7800+ including 700+ scientists Strong foundation for sustained organic growth

AUROBINDO PHARMA LTD.

INFRASTRUCTURE Over 5 million sq meter area spread for state of the art manufacturing facilities. Facilities approved by USFDA, UK-MHRA, FEMIA,INFARMED, PT, MCC South Africa, Anvisa-Brazil and many other regulated and semi-regulated drug Minsitry. R&D

Aurobindo's R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenge

Product Portfolio Therapeutic Segments comprise of Antibiotics, ARVs, CNS, Anti Depressants, Anti Alzheimer, Gastroenterological. Over 250 formulations including immediate release, control release, mouth disintegration tablets, capsules, liquids and Lyophilized Sterile Inj. Huge Product Portfolio of EU CTD Dossiers for Out-Licensing Operations. Marketing Global Marketing Infrastructure through subsidiaries, distribution, joint ventures. Exports to over 100 countries with significant strategic marketing presence in USA, Europe, Latin America, CIS, SEAN. Subsidiaries across the Globe. Milestone Year 2010-11 : The company is in its celebration of Silver Jubilee Year of Operations and CROSSED BILLION DOLLARS mark of consolidated total operating income. 57.3% - Formulation Business (Up By 30% from the previous Year) 64% Business from International Operations. 227 Dossier Filings in Europe (Year 2010-11), cumulative filings 991 Amongst top 5 Pharma companies in India interms of exports and revenue.